Recent advances in cancer therapeutics

Progress in Medicinal Chemistry

Volumn 54, Issue , 2015, Pages 1-63

  Chessum, Nicola ^a   Jones, Keith ^a   Pasqua, Elisa ^a   Tucker, Michael ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Cancer therapeutics; Chaperones; Epigenetics; Histone deacetylases; Kinase inhibitors; Personalised medicine; Protein protein interactions

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; ALIPHATIC CARBOXYLIC ACID; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; BH3 PROTEIN; CHAPERONE INHIBITOR; GELDANAMYCIN; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; IBRUTINIB; LUMINESPIB; NAVITOCLAX; NUTLIN 3; PROTEIN BCL 2; PROTEIN KINASE INHIBITOR; PROTEIN MDM2; PROTEIN P53; RAPAMYCIN DERIVATIVE; ROMIDEPSIN; TETRAPEPTIDE; TRICHOSTATIN A; UNCLASSIFIED DRUG; VEMURAFENIB; VENETOCLAX; [2 (4 TERT BUTYL 2 ETHOXYPHENYL) 4,5 BIS(4 CHLOROPHENYL) 4,5 DIHYDRO 4,5 DIMETHYL 1H IMIDAZOL 1 YL][4 [3 (METHYLSULFONYL)PROPYL] 1 PIPERAZINYL]METHANONE; CHAPERONE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; DRUG EFFECT; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; TUMOR RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; NEOPLASMS;

ANIMALS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MOLECULAR CHAPERONES; NEOPLASMS; PROTEIN KINASE INHIBITORS;

EID: 84923095870     PISSN: 00796468     EISSN: 18757863     Source Type: Book Series    
DOI: 10.1016/bs.pmch.2014.11.002     Document Type: Chapter

References (168)

1. I. Collins, and P. Workman New approaches to molecular cancer therapeutics Nat Chem Biol 2 12 2006 689 700
2. R. Capdeville, E. Buchdunger, J. Zimmerman, and A. Matter Glivec (STI571), a rationally developed, targeted anticancer drug Nat Rev Drug Discov 1 7 2002 493
3. K.A. Dill, and J.L. MacCallum The protein-folding problem, 50 years on Science 338 6110 2012 1042 1046
4. S.L. Lindquist, and J.W. Kelly Chemical and biological approaches for adapting proteostasis to ameliorate protein misfolding and aggregation diseases: progress and prognosis Cold Spring Harb Perspect Biol 3 12 2011 34
5. R.J. Ellis, and A.P. Minton Protein aggregation in crowded environments Biol Chem 387 5 2006 485 497
6. P. Csermely, T. Schnaider, C. Soti, Z. Prohaszka, and G. Nardai The 90-kDa molecular chaperone family: structure, function, and clinical applications. A comprehensive review Pharmacol Ther 79 2 1998 129 168
7. The HSP90 Chaperone Machine Database [Internet]. Available from: http://www.picard.ch/Hsp90Int/index.php.
8. C. Prodromou, S.M. Roe, R. O'Brien, J.E. Ladbury, P.W. Piper, and L.H. Pearl Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone Cell 90 1 1997 65 75
9. C. Prodromou, B. Panaretou, S. Chohan, G. Siligardi, R. O'Brien, and J.E. Ladbury The ATPase cycle of Hsp90 drives a molecular 'clamp' via transient dimerization of the N-terminal domains EMBO J 19 16 2000 4383 4392
10. L. Whitesell, E.G. Mimnaugh, B. De Costa, C.E. Myers, and L.M. Neckers Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation Proc Natl Acad Sci USA 91 18 1994 8324 8328
11. S.M. Roe, C. Prodromou, R. O'Brien, J.E. Ladbury, P.W. Piper, and L.H. Pearl Structural basis for inhibition of the Hsp90 molecular chaperone by the antitumor antibiotics Radicicol and Geldanamycin J Med Chem 42 2 1999 260 266
12. P. Chene ATPases as drug targets: learning from their structure Nat Rev Drug Discov 1 9 2002 665 673
13. D.B. Solit, and G. Chiosis Development and application of Hsp90 inhibitors Drug Discov Today 13 1-2 2008 38 43
14. S. Sharp, K. Jones, and P. Workman Exploiting Cancer Dependence on Molecular Chaperones: HSP90 Inhibitors Past, Present, and Future S. Neidle, Cancer Drug Design and Discovery 2nd ed. 2014 Elsevier Inc London 239 274
15. S. Pacey, R.H. Wilson, M. Walton, M.M. Eatock, A. Hardcastle, and A. Zetterlund A phase I study of the heat shock protein 90 inhibitor Alvespimycin (17-DMAG) given intravenously to patients with advanced solid tumors Clin Cancer Res 17 6 2011 1561 1570
16. T. Taldone, A. Gozman, R. Maharaj, and G. Chiosis Targeting Hsp90: small-molecule inhibitors and their clinical development Curr Opin Pharmacol 8 4 2008 370 374
17. W.K. Oh, M.D. Galsky, W.M. Stadler, S. Srinivas, F. Chu, and G. Bubley Multicenter phase II trial of the heat shock protein 90 inhibitor, retaspimycin hydrochloride (IPI-504), in patients with castration-resistant prostate cancer Urology 78 3 2011 626 630
18. E. McDonald, P. Workman, and K. Jones Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer Curr Top Med Chem 6 11 2006 1091 1107
19. P.A. Brough, W. Aherne, X. Barril, J. Borgognoni, K. Boxall, and J.E. Cansfield 4,5-Diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer J Med Chem 51 2 2008 196 218
20. S.Y. Sharp, C. Prodromou, K. Boxall, M.V. Powers, J.L. Holmes, and G. Box Inhibition of the heat shock protein 90 molecular chaperone in vitro and in vivo by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues Mol Cancer Ther 6 4 2007 1198 1211
21. K.-M.J. Cheung, T.P. Matthews, K. James, M.G. Rowlands, K.J. Boxall, and S.Y. Sharp The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors Bioorg Med Chem Lett 15 14 2005 3338 3343
22. S.Y. Sharp, K. Boxall, M. Rowlands, C. Prodromou, S.M. Roe, and A. Maloney In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors Cancer Res 67 5 2007 2206 2216
23. ClinicalTrials.gov [Internet]. Available from: http://www.clinicaltrials.gov/.
24. E.B. Garon, T. Moran, F. Barlesi, L. Gandhi, L.V. Sequist, and S.-W. Kim Phase II study of the HSP90 inhibitor AUY922 in patients with previously treated, advanced non-small cell lung cancer (NSCLC) J Clin Oncol 30 15 2012
25. A. Kong, D. Rea, S. Ahmed, J.T. Beck, R.L. Lopez, and L. Biganzoli Abstract 530: Phase IB/II study of the HSP90 inhibitor AUY922, in combination with trastuzumab, in patients with HER2+ advanced breast cancer J Clin Oncol 30 15 2012 530
26. C.W. Murray, M.G. Carr, O. Callaghan, G. Chessari, M. Congreve, and S. Cowan Fragment-based drug discovery applied to Hsp90. Discovery of two lead series with high ligand efficiency J Med Chem 53 16 2010 5942 5955
27. B. Graham, J. Curry, T. Smyth, L. Fazal, R. Feltell, and I. Harada The heat shock protein 90 inhibitor, AT13387, displays a long duration of action in vitro and in vivo in non-small cell lung cancer Cancer Sci 103 3 2012 522 527
28. G. Chiosis Discovery and development of purine-scaffold Hsp90 inhibitors Curr Top Med Chem 6 11 2006 1183 1191
29. L. Wright, X. Barril, B. Dymock, L. Sheridan, A. Surgenor, and M. Beswick Structure-activity relationships in purine-based inhibitor binding to HSP90 isoforms Chem Biol 11 6 2004 775 785
30. G. Chiosis, M.N. Timaul, B. Lucas, P.N. Munster, F.F. Zheng, and L. Sepp-Lorenzino A small molecule designed to bind to the adenine nucleotide pocket of Hsp90 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells Chem Biol 8 3 2001 289 299
31. M. Vilenchik, D. Solit, A. Basso, H. Huezo, B. Lucas, and H. He Targeting wide-range oncogenic transformation via PU24FCl, a specific inhibitor of tumor Hsp90 Chem Biol 11 6 2004 787 797
32. L. Llauger, H. He, J. Kim, J. Aguirre, N. Rosen, and U. Peters Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90 J Med Chem 48 8 2005 2892 2905
33. H. He, D. Zatorska, J. Kim, J. Aguirre, L. Llauger, and Y. She Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90 J Med Chem 49 1 2005 381 390
34. K. Lundgren, H. Zhang, J. Brekken, N. Huser, R.E. Powell, and N. Timple BIIB021, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90 Mol Cancer Ther 8 4 2009 921 929
35. M.A. Dickson, S.H. Okuno, M.L. Keohan, R.G. Maki, D.R. D'Adamo, and T.J. Akhurst Phase II study of the HSP90-inhibitor BIIB021 in gastrointestinal stromal tumors Ann Oncol 24 1 2013 252 257
36. J. Shi, R. Van de Water, K. Hong, R.B. Lamer, K.W. Weichert, and C.M. Sandoval EC144 is a potent inhibitor of the heat shock protein 90 J Med Chem 55 17 2012 7786 7795
37. T. Taldone, P.D. Patel, M. Patel, H.J. Patel, C.E. Evans, and A. Rodina Experimental and structural testing module to analyze paralogue-specificity and affinity in the Hsp90 inhibitors series J Med Chem 56 17 2013 6803 6818
38. P.D. Patel, P. Yan, P.M. Seidler, H.J. Patel, W. Sun, and C. Yang Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 Nat Chem Biol 9 11 2013 677 684
39. S. Polier, R.S. Samant, P.A. Clarke, P. Workman, C. Prodromou, and L.H. Pearl ATP-competitive inhibitors block protein kinase recruitment to the Hsp90-Cdc37 system Nat Chem Biol 9 5 2013 307 312
40. M.V. Powers, K. Jones, C. Barillari, I. Westwood, R.L. van Montfort, and P. Workman Targeting HSP70: the second potentially druggable heat shock protein and molecular chaperone? Cell Cycle 9 8 2010 1542 1550
41. A.J. Massey ATPases as drug targets: insights from heat shock proteins 70 and 90 J Med Chem 53 20 2010 7280 7286
42. J. Zhang, P.L. Yang, and N.S. Gray Targeting cancer with small molecule kinase inhibitors Nat Rev Cancer 9 1 2009 28 39
43. P. Cohen Protein kinases-the major drug targets of the twenty-first century? Nat Rev Drug Discov 1 4 2002 309 315
44. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 5600 2002 1912 1934
45. J. Dancey, and E.A. Sausville Issues and progress with protein kinase inhibitors for cancer treatment Nat Rev Drug Discov 2 4 2003 296 313
46. C.E. Allen The design, synthesis and evaluation of novel azaspirocycles as protein kinase inhibitors 2012 The Institute of Cancer Research, The University of London UK
47. M. Cherry, and D.H. Williams Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights Curr Med Chem 11 6 2004 663 673
48. S. Wilhelm, C. Carter, M. Lynch, T. Lowinger, J. Dumas, and R.A. Smith Discovery and development of sorafenib: a multikinase inhibitor for treating cancer Nat Rev Drug Discov 5 10 2006 835 844
49. K. Treiber Daniel, and Neil P. Shah Ins and outs of kinase DFG motifs Chem Biol 20 6 2013 745 746
50. J.F. Ohren, H. Chen, A. Pavlovsky, C. Whitehead, E. Zhang, and P. Kuffa Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition Nat Struct Mol Biol 11 12 2004 1192 1197
51. J. Singh, R.C. Petter, T.A. Baillie, and A. Whitty The resurgence of covalent drugs Nat Rev Drug Discov 10 4 2011 307 317
52. R. Mah, J.R. Thomas, and C.M. Shafer Drug discovery considerations in the development of covalent inhibitors Bioorg Med Chem Lett 24 1 2014 33 39
53. Centerwatch. Available from http://centerwatch.com/drug-information/fda-approved-drugs/.
54. G. Bollag, J. Tsai, J. Zhang, C. Zhang, P. Ibrahim, and K. Nolop Vemurafenib: the first drug approved for BRAF-mutant cancer Nat Rev Drug Discov 11 11 2012 873 886
55. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 6892 2002 949 954
56. P.M. Pollock, and P.S. Meltzer A genome-based strategy uncovers frequent BRAF mutations in melanoma Cancer Cell 2 1 2002 5 7
57. C. Greenman, P. Stephens, R. Smith, G.L. Dalgliesh, C. Hunter, and G. Bignell Patterns of somatic mutation in human cancer genomes Nature 446 7132 2007 153 158
58. P.T.C. Wan, M.J. Garnett, S.M. Roe, S. Lee, D. Niculescu-Duvaz, and V.M. Good Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 6 2004 855 867
59. J. Tsai, J.T. Lee, W. Wang, J. Zhang, H. Cho, and S. Mamo Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity Proc Natl Acad Sci USA 105 8 2008 3041 3046
60. T. Rajakulendran, M. Sahmi, M. Lefrancois, F. Sicheri, and M. Therrien A dimerization-dependent mechanism drives RAF catalytic activation Nature 461 7263 2009 542 545
61. C.A. Hall-Jackson, P.A. Eyers, P. Cohen, M. Goedert, F.T. Boyle, and N. Hewitt Paradoxical activation of Raf by a novel Raf inhibitor Chem Biol 6 8 1999 559 568
62. A.D. Cox, and C.J. Der The RAF inhibitor paradox revisited Cancer Cell 21 2 2012 147 149
63. G. Bollag, P. Hirth, J. Tsai, J. Zhang, P.N. Ibrahim, and H. Cho Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 7315 2010 596 599
64. E. Romano, S. Pradervand, A. Paillusson, J. Weber, K. Harshman, and K. Muehlethaler Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression Clin Cancer Res 19 20 2013 5749 5757
65. F. Su, W.D. Bradley, Q. Wang, H. Yang, L. Xu, and B. Higgins Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation Cancer Res 72 4 2012 969 978
66. R. Kuppers Mechanisms of B-cell lymphoma pathogenesis Nat Rev Cancer 5 4 2005 251 262
67. R.E. Davis, V.N. Ngo, G. Lenz, P. Tolar, R.M. Young, and P.B. Romesser Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 7277 2010 88 92
68. Z. Pan, H. Scheerens, S.-J. Li, B.E. Schultz, P.A. Sprengeler, and L.C. Burrill Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2 1 2007 58 61
69. M.A. Fabian, W.H. Biggs, D.K. Treiber, C.E. Atteridge, M.D. Azimioara, and M.G. Benedetti A small molecule-kinase interaction map for clinical kinase inhibitors Nat Biotechnol 23 3 2005 329 336
70. D.W. Fry, A.J. Bridges, W.A. Denny, A. Doherty, K.D. Greis, and J.L. Hicks Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor Proc Natl Acad Sci USA 95 20 1998 12022 12027
71. M.S. Cohen, C. Zhang, K.M. Shokat, and J. Taunton Structural bioinformatics-based design of selective, irreversible kinase inhibitors Science 308 5726 2005 1318 1321
72. L.A. Honigberg, A.M. Smith, M. Sirisawad, E. Verner, D. Loury, and B. Chang The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci USA 107 29 2010 13075 13080
73. K. Sanderson Irreversible kinase inhibitors gain traction Nat Rev Drug Discov 12 9 2013 649 651
74. D. Cross, S. Ashton, C. Nebhan, C. Eberlein, M.R.V. Finlay, and G. Hughes Abstract A109: AZD9291: an irreversible, potent and selective third generation tyrosine kinase inhibitor (TKI) targeting EGFR activating (EGFRm +) and resistance (T790M) mutations in advanced lung adenocarcinoma Mol Cancer Ther 12 2013 A109
75. M.R.V. Finlay, M. Anderton, S. Ashton, P. Ballard, P.A. Bethel, and M.R. Box Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor J Med Chem 57 20 2014 8249 8267
76. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, and H. Lee Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 7326 2010 973 977
77. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, and A.K. Cipolla Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 6 2010 683 695
78. J.A. Woyach, R.R. Furman, T.-M. Liu, H.G. Ozer, M. Zapatka, and A.S. Ruppert Resistance mechanisms for the Bruton's tyrosine kinase inhibitor Ibrutinib N Engl J Med 370 24 2014 2286 2294
79. R.R. Furman, S. Cheng, P. Lu, M. Setty, A.R. Perez, and A. Guo Ibrutinib resistance in chronic lymphocytic leukemia N Engl J Med 370 24 2014 2352 2354
80. M. Talpaz, N.P. Shah, H. Kantarjian, N. Donato, J. Nicoll, and R. Paquette Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias N Engl J Med 354 24 2006 2531 2541
81. H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, and B. Wassmann Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL N Engl J Med 354 24 2006 2542 2551
82. H. Daub, K. Specht, and A. Ullrich Strategies to overcome resistance to targeted protein kinase inhibitors Nat Rev Drug Discov 3 12 2004 1001 1010
83. Z.A. Knight, H. Lin, and K.M. Shokat Targeting the cancer kinome through polypharmacology Nat Rev Cancer 10 2 2010 130 137
84. A. Anighoro, J. Bajorath, and G. Rastelli Polypharmacology: challenges and opportunities in drug discovery J Med Chem 57 19 2014 7874 7887
85. B. Apsel, J.A. Blair, B. Gonzalez, T.M. Nazif, M.E. Feldman, and B. Aizenstein Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases Nat Chem Biol 4 11 2008 691 699
86. T. Kouzarides Chromatin modifications and their function Cell 128 4 2007 693 705
87. V.G. Allfrey, R. Faulkner, and A.E. Mirsky Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis Proc Natl Acad Sci USA 51 5 1964 786 794
88. M. Dokmanovic, C. Clarke, and P.A. Marks Histone deacetylase inhibitors: overview and perspectives Mol Cancer Res 5 10 2007 981 989
89. K.B. Glaser HDAC inhibitors: clinical update and mechanism-based potential Biochem Pharmacol 74 5 2007 659 671
90. A.J.M. de Ruijter, A.H. van Gennip, H.N. Caron, S. Kemp, and A.B.P. van Kuilenburg Histone deacetylases (HDACs): characterization of the classical HDAC family Biochem J 370 3 2003 737 749
91. I. Gregoretti, Y.-M. Lee, and H.V. Goodson Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis J Mol Biol 338 1 2004 17 31
92. P.A. Marks Histone deacetylase inhibitors: a chemical genetics approach to understanding cellular functions BBA-Gene Regul Mech 1799 10-12 2010 717 725
93. M.S. Finnin, J.R. Donigian, A. Cohen, V.M. Richon, R.A. Rifkind, and P.A. Marks Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors Nature 401 6749 1999 188 193
94. M. Dokmanovic, and P.A. Marks Prospects: histone deacetylase inhibitors J Cell Biochem 96 2 2005 293 304
95. J.E. Bolden, M.J. Peart, and R.W. Johnstone Anticancer activities of histone deacetylase inhibitors Nat Rev Drug Discov 5 9 2006 769 784
96. R.W. Johnstone Histone-deacetylase inhibitors: novel drugs for the treatment of cancer Nat Rev Drug Discov 1 4 2002 287 299
97. X. Ma, H.H. Ezzeldin, and R.B. Diasio Histone deacetylase inhibitors: current status and overview of recent clinical trials Drugs 69 14 2009 1911 1934
98. M. Grunstein Histone acetylation in chromatin structure and transcription Nature 389 6649 1997 349 352
99. M. Abe, and D.W. Kufe Sodium butyrate induction of milk-related antigens in human MCF-7 breast carcinoma cells Cancer Res 44 10 1984 4574 4577
100. T. Davis, C. Kennedy, Y.-E. Chiew, C.L. Clarke, and A. deFazio Histone deacetylase inhibitors decrease proliferation and modulate cell cycle gene expression in normal mammary epithelial cells Clin Cancer Res 6 11 2000 4334 4342
101. Q. Zhou, Z.K. Melkoumian, A. Lucktong, M. Moniwa, J.R. Davie, and J.S. Strobl Rapid induction of histone hyperacetylation and cellular differentiation in human breast tumor cell lines following degradation of histone deacetylase-1 J Biol Chem 275 45 2000 35256 35263
102. P.N. Munster, T. Troso-Sandoval, N. Rosen, R. Rifkind, P.A. Marks, and V.M. Richon The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces differentiation of human breast cancer cells Cancer Res 61 23 2001 8492 8497
103. W.K. Kelly, and P.A. Marks Drug insight: histone deacetylase inhibitors - development of the new targeted anticancer agent suberoylanilide hydroxamic acid Nat Rev Clin Oncol 2 3 2005 150 157
104. K. Ververis, A. Hiong, T.C. Karagiannis, and P.V. Licciardi Histone deacetylase inhibitors (HDACIs): multitargeted anticancer agents Biologics 7 2013 47 60
105. M.H. Kirschbaum, K.A. Foon, P. Frankel, C. Ruel, B. Pulone, and J.M. Tuscano A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study Leuk Lymphoma 55 10 2014 2301 2304
106. C. Friend, W. Scher, J.G. Holland, and T. Sato Hemoglobin synthesis in murine virus-induced leukemic cells in vitro: stimulation of erythroid differentiation by dimethyl sulfoxide Proc Natl Acad Sci USA 68 2 1971 378 382
107. M. Tanaka, J. Levy, M. Terada, R. Breslow, R.A. Rifkind, and P.A. Marks Induction of erythroid differentiation in murine virus infected eythroleukemia cells by highly polar compounds Proc Natl Acad Sci USA 72 3 1975 1003 1006
108. R.C. Reuben, R.L. Wife, R. Breslow, R.A. Rifkind, and P.A. Marks A new group of potent inducers of differentiation in murine erythroleukemia cells Proc Natl Acad Sci USA 73 3 1976 862 866
109. R. Breslow, B. Jursic, Z.F. Yan, E. Friedman, L. Leng, and L. Ngo Potent cytodifferentiating agents related to hexamethylenebisacetamide Proc Natl Acad Sci USA 88 13 1991 5542 5546
110. V.M. Richon, Y. Webb, R. Merger, T. Sheppard, B. Jursic, and L. Ngo Second generation hybrid polar compounds are potent inducers of transformed cell differentiation Proc Natl Acad Sci USA 93 12 1996 5705 5708
111. P.A. Marks, M. Sheffery, and R.A. Rifkind Induction of transformed cells to terminal differentiation and the modulation of gene expression Cancer Res 47 3 1987 659 666
112. M. Yoshida, M. Kijima, M. Akita, and T. Beppu Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A J Biol Chem 265 28 1990 17174 17179
113. W.K. Kelly, V.M. Richon, O. O'Connor, T. Curley, B. MacGregor-Curtelli, and W. Tong Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously Clin Cancer Res 9 10 2003 3578 3588
114. P. Münster, D. Marchion, E. Bicaku, M. Schmitt, J.H. Lee, and R. DeConti Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor Epirubicin in advanced solid tumors: a clinical and translational study J Clin Oncol 25 15 2007 1979 1985
115. R. Lavoie, G. Bouchain, S. Frechette, S.H. Woo, E.A. Khalil, and S. Leit Design and synthesis of a novel class of histone deacetylase inhibitors Bioorg Med Chem Lett 11 21 2001 2847 2850
116. J.A. Plumb, P.W. Finn, R.J. Williams, M.J. Bandara, M.R. Romero, and C.J. Watkins Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101 Mol Cancer Ther 2 8 2003 721 728
117. L. Fuino, P. Bali, S. Wittmann, S. Donapaty, F. Guo, and H. Yamaguchi Histone deacetylase inhibitor LAQ824 down-regulates Her-2 and sensitizes human breast cancer cells to trastuzumab, taxotere, gemcitabine, and epothilone B Mol Cancer Ther 2 10 2003 971 984
118. L.R. Molife, and J.S. de Bono Belinostat: clinical applications in solid tumors and lymphoma Expert Opin Investig Drugs 20 12 2011 1723 1732
119. T.H. Manoharan, J.A. Burgess, D. Ho, C.L. Newell, and W.E. Fahl Integration of a mutant c-Ha-ras oncogene into C3H/10 T1/2 cells and its relationship to tumorigenic transformation Carcinogenesis 6 9 1985 1295 1301
120. N. Shigematsu, H. Ueda, S. Takase, H. Tanaka, K. Yamamoto, and T. Tada FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. II. Structure determination J Antibiot 47 1994 311 314
121. R. Wang, T. Brunner, L. Zhang, and Y. Shi Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression Oncogene 17 12 1998 1503 1508
122. G. Rajgolikar, K. Chan, and H.-C. Wang Effects of a novel antitumor depsipeptide, FR901228, on human breast cancer cells Breast Cancer Res Treat 51 1 1998 29 38
123. H. Nakajima, Y.B. Kim, H. Terano, M. Yoshida, and S. Horinouchi FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor Exp Cell Res 241 1 1998 126 133
124. S.J. Whittaker, M.-F. Demierre, E.J. Kim, A.H. Rook, A. Lerner, and M. Duvic Final results from a multicenter, international, pivotal study of Romidepsin in refractory cutaneous T-cell lymphoma J Clin Oncol 28 29 2010 4485 4491
125. N. Khan, M. Jeffers, S. Kumar, C. Hackett, F. Boldog, and N. Khramtsov Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors Biochem J 409 2 2008 581 589
126. W.S. Xu, R.B. Parmigiani, and P.A. Marks Histone deacetylase inhibitors: molecular mechanisms of action Oncogene 26 37 2007 5541 5552
127. W.K. Rasheed, R.W. Johnstone, and H.M. Prince Histone deacetylase inhibitors in cancer therapy Expert Opin Investig Drugs 16 5 2007 659 678
128. W. Löscher Basic pharmacology of Valproate CNS Drugs 16 10 2002 669 694
129. A. Atmaca, S.E. Al-Batran, A. Maurer, A. Neumann, T. Heinzel, and B. Hentsch Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial Br J Cancer 97 2 2007 177 182
130. M. Candelaria, D. Gallardo-Rincón, C. Arce, L. Cetina, J. Aguilar-Ponce, and Ó. Arrieta A phase II study of epigenetic therapy with hydralazine and magnesium valproate to overcome chemotherapy resistance in refractory solid tumors Ann Oncol 18 9 2007 1529 1538
131. A.V. Bieliauskas, and M.K.H. Pflum Isoform-selective histone deacetylase inhibitors Chem Soc Rev 37 7 2008 1402 1413
132. W.K. Kelly, O.A. O'Connor, L.M. Krug, J.H. Chiao, M. Heaney, and T. Curley Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer J Clin Oncol 23 17 2005 3923 3931
133. V. Sandor, S. Bakke, R.W. Robey, M.H. Kang, M.V. Blagosklonny, and J. Bender Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms Clin Cancer Res 8 3 2002 718 728
134. G. Garcia-Manero, S. Assouline, J. Cortes, Z. Estrov, H. Kantarjian, and H. Yang Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia Blood 112 4 2008 981 989
135. G. Garcia-Manero, H. Yang, C. Bueso-Ramos, A. Ferrajoli, J. Cortes, and W.G. Wierda Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes Blood 111 3 2008 1060 1066
136. E. Lech-Maranda, E. Robak, A. Korycka, and T. Robak Depsipeptide (FK228) as a novel histone deacetylase inhibitor: mechanism of action and anticancer activity Mini-Rev Med Chem 7 10 2007 1062 1069
137. T.L. Nero, C.J. Morton, J.K. Holien, J. Wielens, and M.W. Parker Oncogenic protein interfaces: small molecules, big challenges Nat Rev Cancer 14 2014 248 262
138. P.E. Czabotar, and G. Lessene Bcl-2 family proteins as therapeutic targets Curr Pharm Des 16 2010 3132 3148
139. C. Tse, A.R. Shoemaker, J. Adickes, M.G. Anderson, J. Chen, and S. Jin ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor Cancer Res 68 2008 3421 3428
140. M.D. Wendt Discovery of ABT-263, a Bcl-family protein inhibitor: observations on targeting a large protein-protein interaction Expert Opin Drug Discov 3 2008 1123 1143
141. A.M. Petros, J. Dinges, D.J. Augeri, S.A. Baumeister, D.A. Betebenner, and M.G. Bures Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis J Med Chem 49 2006 656 663
142. T. Oltersdorf, S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, and B.A. Belli An inhibitor of Bcl-2 family proteins induces regression of solid tumors Nature 435 2005 677 681
143. M. Sattler, H. Liang, D. Netesheim, R.P. Meadows, J.E. Harlan, and M. Eberstadt Structure of Bcl-xL-Bak peptide complex: recognition between regulators of apoptosis Science 275 1997 983 986
144. H. Mao, P.J. Hajduk, R. Craig, R. Bell, T. Borre, and S.W. Fesik Rational design of diflunisal analogues with reduced affinity for human serum albumin J Am Chem Soc 123 43 2001 10429 10435
145. P.J. Hajduk, R. Mendoza, A.M. Petros, J.R. Huth, M. Bures, and S.W. Fesik Ligand binding to domain-3 of human serum albumin: a chemometric analysis J Comput-Aided Mol Des 17 2003 93 102
146. L. Gandhi, D.R. Camidge, M. Ribeiro de Oliveira, P. Bonomi, D. Gandara, and D. Khaira Phase I study of navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors J Clin Oncol 29 2011 909 916
147. C.M. Rudin, C.L. Hann, E.B. Garon, M. Ribeiro de Oliveira, P.D. Bonomi, and D.R. Camidge Phase II study of single-agent Navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer Clin Cancer Res 18 2012 3163 3169
148. J. Chen, S. Jin, V. Abraham, X. Huang, B. Liu, and M.J. Mitten The Bcl-2/Bcl-XL/Bcl-w inhibitor, Navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo Mol Cancer Ther 10 2011 2340 2349
149. R.B. Corcoran, K.A. Cheng, A.N. Hata, A.C. Faber, H. Ebi, and E.M. Coffee Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models Cancer Cell 23 2013 121 128
150. B. Wang, Z. Ni, X. Dai, L. Qin, X. Li, and L. Xu The Bcl-2/xL inhibitor ABT-263 increases the stability of Mcl-1 mRNA and protein in hepatocellular carcinoma cells Mol Cancer 13 2014 98
151. D.J. Burgess Apoptosis refined and lethal Nat Rev Cancer 13 2013 79
152. A.J. Souers, J.D. Leverson, E.R. Boghaert, S.L. Ackler, N.D. Catron, and J. Chen ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets Nat Med 19 2013 202 210
153. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 Science 303 2004 844 848
154. K.K. Hoe, C.S. Verma, and D.P. Lane Drugging the p53 pathway: understanding the route to clinical efficacy Nat Rev Drug Discov 13 2014 217 235
155. C.J. Brown, S. Lain, C.S. Verma, A.R. Fersht, and D.P. Lane Awakening guardian angels: drugging the p53 pathway Nat Rev Cancer 9 2009 862 872
156. P. Chene Inhibiting the p53-MDM2 interaction: an important target for cancer therapy Nat Rev Cancer 3 2003 102 109
157. B. Vu, P. Wovkulich, G. Pizzolato, A. Lovey, Q. Ding, and N. Jiang Discovery of RG7112: a small-molecule MDM2 inhibitor in clinical development ACS Med Chem Lett 4 2013 466 469
158. D. Drygin, S.E. O'Brien, R.D. Hannan, G.A. McArthur, and D.D. Von Hoff Targeting the nucleolus for cancer-specific activation of p53 Drug Discov Today 19 2014 259 265
159. Q. Ding, Z. Zhang, J.J. Liu, N. Jiang, J. Zhang, and T.M. Ross Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development J Med Chem 56 2013 5979 5983
160. H. Pópulo, J. Lopes, and P. Soares The mTOR signalling pathway in human cancer Int J Mol Sci 13 2012 1886 1918
161. A.S. Strimpakos, E.M. Karapanagiotou, M.W. Saif, and K.N. Syrigos The role of mTOR in the management of solid tumors: an overview Cancer Treat Rev 35 2009 148 159
162. M. Laplante, and D. Sabatini mTOR signaling in growth control and disease Cell 149 2012 274 293
163. D.A. Fruman, and C. Rommel PI3K and cancer: lessons, challenges and opportunities Nat Rev Drug Discov 13 2014 140 156
164. Y.Y. Zaytseva, J.D. Valentino, P. Gulhati, and B.M. Evers mTOR inhibitors in cancer therapy Cancer Lett 319 2012 1 7
165. B. Seto Rapamycin and mTOR: a serendipitous discovery and implications for breast cancer Clin Transl Med 1 2012 29
166. Y.J. Zhang, Y. Duan, and X.F.S. Zheng Targeting the mTOR kinase domain: the second generation of mTOR inhibitors Drug Discov Today 16 2011 325 331
167. S. Faivre, G. Kroemer, and E. Raymond Current development of mTOR inhibitors as anticancer agents Nat Rev Drug Discov 5 2006 671 688
168. A.A. Ivanov, F.R. Khuri, and H. Fu Targeting protein-protein interactions as an anticancer strategy Trends Pharmacol Sci 34 2013 393 400